With regard to hiPSC-CM-based cell replacement therapy, the combination of cardiomyocyte-specific BIN1 induction and tissue engineering approaches employing micropatterning of cells [6] may advance the development of cardiac patches and enhance the therapeutic potential of these cells for the treatment of patients with heart failure. The gene discussed is BIN1; the disease is heart failure.